Description
Miglustat acts as an inhibitor of glucosylceramide synthase. By slowing the production of glycosphingolipids, it reduces the overall lipid trafficking burden on the defective NPC1 and NPC2 proteins, decreasing intracellular lipid toxicity.
User Reviews
Log in to leave a review.
No reviews yet for this remedy.